18 December 2024NewsAmericasRajiv Nayar President HTD Biosystems, Chuck Sholtz Vice President Intellectual Property Nutcracker Therapeutics, Benjamin Pelletier Partner Haynes & Boone

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

The patent landscape for biologics, biosimilars, and advanced therapeutic antibodies is undergoing rapid change, presenting both opportunities and challenges for innovators and manufacturers. This panel will explore current issues and strategies in this dynamic field.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UK court upholds EU SPC precedent, rejecting MSD’s appeal

Fish & Richardson doubles down in Chicago with new office

GSK seeks damages hike in ‘skinny label’ case

UPC orders Sanofi to fix ‘deficiencies’ in prostate cancer drug case

Dutch court axes Biogen’s MS patent, clearing way for generics

Munck Wilson Mandala brings in first-chair patent litigator from McGuireWoods

Goodwin hires ‘impressive’ partner for NY office

Fed Circ grants Teva temporary pause in Orange Book feud

WATCH: What are the latest challenges in patenting biologics, biosimilars, and bispecific antibodies?

Editor's picks

Editor's picks

More features